

ANIMAL WELFARE & ETHICAL REVIEW BODY

Minutes: 1:30pm, Tuesday 18th May 2021, Online meeting

	Items.	AWERB Outcome
1	Attendance: 11 x AWERB members, 1 x observers	
2	Minutes of the last meeting.	
2.1	Up to date and sent on to ASU Management Board.	Complete
3	Matters arising from the notes of previous meeting (27 th April 2021)	
3.1	3.1 Formalising draft PPL application review deadlines and production of guidance documents.	Ongoing
3.2	3.2 User guidance documents for internal Tissue Sharing Network to be review in AOB.	Ongoing
3.3	3.3 Structure of AWERB continues to be discussed at ASU Management Board (ASUMB)	Ongoing
3.4	3.4 Future AWERB auditing of techniques – will remain as ongoing action for ASUMB.	Ongoing
3.5	3.6 ASU to formalise enrichment piloting to be discussed within NACWO meetings and reported to AWERB.	Complete
3.6	4.2 Large animal transport acclimatisation policy does not require amending. Arrival and training timelines should be written into all future and existing PSBs. Communicate with relevant research unit management board.	6-month review follow up
3.7	6.11 Explore potential updated options for facilitating anonymous whistleblowing, to be discussed at ASUMB Board.	Ongoing
3.8	10.1 PPLAmend.2Dec20 Resubmission. Sci Reviewer met with applicant to further discuss scientific aspects of application. Protocol to include independent (NVS) assessment for suitability for animals to go forward to next stage	Amendment approved subject to these changes
3.9	12.1.1.1.1 April UIN.3 clarifications received and approved	Complete
3.10	12.2.1.1.1 April VIN.2 clarifications received and approved	Complete

3.11	2 x instances of user error, reported to Home Office.	Complete
4	Chair's Report	
4.1	(none)	
5	NTCO Report.	
5.1	May NTCO review. Mixture of CPD activities. Good number of observations present. Future reviews will include assessment of refined rodent handling training.	
5.2	ASU Access form has been updated to included info to clarify signature needs and evidence of mask fitting.	
5.3	Licensee training course held	
5.4	3Rs Symposium next week.	
5.5	Training and competency records checked for all PPL and PPL Amendment applicants.	
6	NIO Report.	
6.1	Selection of relevant upcoming 3Rs webinars and CPD opportunities circulated to PPL holders, PIL holders and ASU technicians.	
6.2	Deputy NIO Attending and assisting lead NACWO in future NACWO meetings.	
7	NVS Report.	
7.1	Standard condition 18 Report, Amendment to PPL applied for to include adverse effect and prevent future instances.	Complete

<p>8</p> <p>8.1</p> <p>8.2</p> <p>8.3</p> <p>8.4</p> <p>8.5</p>	<p>NACWO reports.</p> <p>Lead NACWO appointed for NACWO Team. Monthly NACWO meetings to be held to discuss welfare and enrichment. Outcomes of NACWO meetings will be reported to AWERB via NACWO report.</p> <p>Tissue sharing currently being facilitated by NACWOs</p> <p>ASU Technician presenting at GW4 3Rs Symposium</p> <p>Encouragement from NACWOs led to researcher submissions of refinements to GW4 3Rs Symposium.</p> <p>Increase in PSBs and activities across some units.</p>	
<p>9</p> <p>9.1</p>	<p>Project Licences – New Applications.</p> <p>PPL.1May21.</p> <p>Aims: To investigate the biology of the kidney to identify novel drug targets for the treatment of kidney disease</p> <p>Harms: Primarily uses GAA mouse lines including some in combination with disease models to enable characterisation of both normal and pathological kidney function. Some likelihood of animals experiencing overt signs of disease but with well-defined endpoint to limit suffering. A large animal model included to facilitate translational studies.</p> <p>Benefits: The data generated will mainly be of benefit to the overall knowledge of kidney function and renal disease with a focus on important cellular signalling pathways in the kidney and how they can be manipulated in a beneficial manner to prevent or slow the progression of kidney disease. The planned research will generate new information on how the kidney works, identify new drug targets, and assess the effectiveness of novel treatments at preventing kidney disease.</p> <p>Discussion:</p> <ul style="list-style-type: none"> • Disease models and induction methods • Minimising adverse effects • Monitoring schedules and scoring • Refinements to use of metabolic cages • Sham surgery vs controls • Animal numbers • Drug administration • Handling refinements 	<p>Approved subject to clarifications</p>
<p>10</p>	<p>Project Licences – Amendments.</p>	

10.1	<p>PPLAmend.1May21. Amendment to include short term postoperative recovery.</p> <p>Discussion:</p> <ul style="list-style-type: none"> • Translational benefit • Threshold criteria and monitoring parameters • Harm vs benefit on prolonged sedation • Scientific justification for waking • Ensure contingency present in PSB • Monitoring requirements • Management of suffering • Animal numbers • Written response for Monday • CPD update 	Rejected at current stage.
10.2	<p>PPLAmend.2May21 Amendment to include adverse effect and additional injection route.</p> <p>Discussion:</p> <ul style="list-style-type: none"> • Scientific justification required for additional injection route • Non-recovery procedure • Refinement to technique 	Approved to include adverse event. For further amendment, scientific justification required.
10.3	<p>PPLAmend.3May21. Amendment to include new injury model</p> <p>Discussion:</p> <ul style="list-style-type: none"> • Clear scientific benefit • Clarity required for number of surgical steps • Typical experience required • Justification of use of analgesic • Model refinement • Set timepoints required for manual expression of bladder frequency, especially overnight. • Catheterisation • Lack of clarity due to older PPL format 	Not approved in current form. Resubmission required to full AWERB
10.4	<p>PPLAmend.4May21. Minor wording amendment to include wider range of cell lines.</p>	Approved
11	Project Licence Reviews	

11.1 11.1.1	Mid Term Reviews. (none)	
11.2	Home Office Retrospective Reviews. (None)	
11.3 11.3.1	Final Reviews. PPLFR.1May21 <ul style="list-style-type: none"> • Licence transferred from another institution • Fewer animals than predicted due to relocation and COVID-19 pandemic • One Section 18 at previous institution • CPD update required 	Approved subject to CPD record update
12	Report on Non-Regulated Projects UIN and VIN applications.	
12.1	Non-Regulated Projects – UINs Reviewed: UIN.1 & 2 AWERB approved: UIN.1 AWERB approved pending clarifications: None AWERB did not yet approve: UIN.2	Secretary to inform
12.1.1 12.1.1.1	UINs to note: (None) UIN.2: Schedule 1 methods listed are incorrect. Contact NVS to discuss appropriate methods. Address 3Rs and explain sample size calculation.	
12.2	Non-Regulated Projects – VINs. Reviewed: VIN.1 AWERB approved: VIN.1 AWERB approved pending clarifications: None AWERB did not yet approved: None.	Secretary to inform
12.2.1 12.2.1.1	VINs to note: (None)	

13	Non-Regulated Projects - UIN and VIN amendments	
13.1	(None)	
14	AWERB Hub. (None)	
16	For Information. (None)	
17	Any Other Business.	
17.1	iTSN Guidance Documents.	Approved. Soft launch for AWERB members. Awaiting Etiquette document
17.2	Clinical ethics panel set up by local veterinary group.	
18.	Dates of Next Meetings (Online until further notice): Tuesday 15th June 2021 Tuesday 20th July 2021	